Therapeutic antibodies
Currently, we offer 21 different therapeutic monoclonal antibodies from EU licensed drugs for use in R&D, preclinical development, process development, manufacturing & clinical development. Research-relevant quantities of the original drug are available as aliquot or dilution.
NEW – see our 3 new PD-L1 mAbs:
- Atezolizumab (Tecentirq®)
- Avelumab (Bavencio®)
- Durvalumab (Imfinzi®)
Drug name | Therapeutic molecule | Antigen |
|---|---|---|
|
Bevacizumab |
VEGF-A |
|
|
Avelumab |
PD-L1 |
|
|
Secukinumab |
IL 17A |
|
|
Ramucirumab |
VEGFR2 |
|
|
Daratumumab |
CD38 |
|
|
Etanercept |
TNF-α |
|
|
Cetuximab |
EGFR |
|
|
Obinutuzumab |
CD20 |
|
|
Trastuzumab |
HER2 |
|
|
Adalimumab |
TNF-α |
|
|
Durvalumab |
PD-L1 |
|
|
Pembrolizumab |
PD-1 |
|
|
Rituximab |
CD20 |
|
|
Nivolumab |
PD-1 |
|
|
Denosumab |
RANKL |
|
|
Infliximab |
TNF-α |
|
|
Tocilizumab |
IL-6 R |
|
|
Golimumab |
TNF-α |
|
|
Ustekinumab |
IL-12 |
|
|
Palivizumab |
RSV protein F |
|
|
Atezolizumab |
PD-L1 |
Showing all 21 results
